

AMS HEALTH SCIENCES INC
Form 10QSB
November 20, 2007

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-QSB

**(X) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the quarterly period ended September 30, 2007

or

**() TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the transition period from _____ to _____

Commission File Number: 001-13343

AMS HEALTH SCIENCES, INC.

(Exact name of Small Business Issuer as specified in its charter)

Oklahoma

(State or other jurisdiction of incorporation or organization)

73-1323256

(I.R.S. Employer Identification No.)

711 NE 39th Street

Oklahoma City, Oklahoma 73105

(Address of principal executive offices)

(405) 842-0131

(Issuer's telephone number, including area code)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

X

No

Indicate by check mark whether the issuer is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

No

X

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

On November 12, 2007 we had outstanding 8,515,824 shares of our common stock, \$0.0001 par value.

Transitional Small Business Disclosure Format (check one):

Yes

No

X

AMS HEALTH SCIENCES, INC.
QUARTERLY REPORT ON FORM 10-QSB
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007

Table of Contents

Part I Financial Information	3
Item 1. Financial Statements	3
Consolidated Balance Sheets	3
Consolidated Statements of Operations	4
Consolidated Statements of Cash Flows	5
Notes to Consolidated Financial Statements	6
Report of Independent Registered Public Accounting Firm	20
Item 2. Management’s Discussion and Analysis or Plan of Operation	21
Item 3. Controls and Procedures	31
Part II –Other Information	32
Item 1. Legal Proceedings	32
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3. Defaults Upon Senior Securities	32
Item 4. Submission of Matters to a Vote of Security Holders	32
Item 5. Other Information	32
Item 6. Exhibits	33

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements under the caption “Item 2 – Management’s Discussion and Analysis or Plan of Operation” constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Certain, but not necessarily all, of such forward-looking statements can be identified by the use of forward-looking terminology such as “anticipates”, “believes”, “expects”, “may”, “will”, or “should” or other variations thereon, or by discussions of strategies that involve risks and uncertainties. Our actual results or industry results may be materially different from any future results expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include general economic and business conditions; our ability to implement our business and acquisition strategies; changes in the network marketing industry and changes in consumer preferences; competition; availability of key personnel; increasing operating costs; unsuccessful advertising and promotional efforts; changes in brand awareness; acceptance of new product offerings; changes in, or the failure to comply with, government regulations (especially food and drug laws and regulations); product liability matters; our ability to obtain financing for future acquisitions and other factors. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

PART I—FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2007 AND DECEMBER 31, 2006
(UNAUDITED)

ASSETS	September 30, 2007	December 31, 2006
	(Unaudited)	
CURRENT ASSETS:		
Cash	\$ 157,775	\$ 269,726
Marketable securities, available for sale, at fair value	-	793,183
Receivables	17,586	44,576
Inventory, net	485,837	700,664
Other assets	68,875	77,319
Current assets of discontinued operations	2,139	110,521
Total current assets	732,212	1,995,989
RESTRICTED SECURITIES	81,513	78,723
RECEIVABLES	17,687	28,374
PROPERTY AND EQUIPMENT, net	2,569,185	2,794,393
COVENANTS NOT TO COMPETE and other intangibles, net	289,107	324,553
OTHER ASSETS	320,015	457,344
NONCURRENT ASSETS OF DISCONTINUED OPERATIONS	800,000	1,253,480
TOTAL	\$ 4,809,719	\$ 6,932,856
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable	\$ 211,188	\$ 559,920
Accrued commissions and bonuses	261,454	268,717
Accrued other expenses	254,478	400,204
Accrued sales tax liability	224,874	200,481
Deferred compensation	98,657	96,378
Notes payable	726,664	257,542
Capital lease obligations	117,383	104,591
Current liabilities of discontinued operations	315,875	360,582
Total current liabilities	2,210,573	2,248,415
LONG-TERM LIABILITIES:		
Notes payable	388,555	625,220
Capital lease obligations	134,887	95,527
Deferred compensation	213,758	281,101
Lease abandonment liability	-	55,123
Liabilities of discontinued operations	1,338,576	1,570,359
Total liabilities	4,286,349	4,875,745
COMMITMENT AND CONTINGENCIES (Note 8)		
STOCKHOLDERS' EQUITY		
Common stock - \$.0001 par value; authorized 495,000,000 shares; issued 9,107,419 and 9,107,419 shares; outstanding 8,515,824 and 8,515,824 shares, respectively	\$ 905	\$ 905
Paid-in capital	23,670,379	23,609,734

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

Notes receivable for exercise of options	(31,000)	(31,000)
Accumulated deficit	(20,484,135)	(18,889,749)
Total capital and accumulated deficit	3,156,149	4,689,890
Less cost of treasury stock (591,595 shares)	(2,632,779)	(2,632,779)
Total stockholders' equity	523,370	2,057,111
TOTAL	\$ 4,809,719	\$ 6,932,856

See notes to consolidated financial statements.

3

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE PERIODS ENDED SEPTEMBER 30, 2007 AND 2006

(UNAUDITED)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2007	2006	2007	2006
Net sales	\$ 1,706,402	\$ 2,410,251	\$ 6,121,032	\$ 7,316,600
Cost of sales:				
Cost of product	602,431	629,218	1,863,837	2,121,459
Associate commissions	489,291	793,570	1,884,863	2,353,968
Total cost of sales	1,091,722	1,422,788	3,748,700	4,475,427
Gross profit	614,680	987,463	2,372,332	2,841,173
Marketing and administrative expenses:				
Marketing	106,587	211,127	489,114	454,122
Administrative	881,924	1,134,913	2,695,829	2,589,997
Total marketing and administrative expenses	988,511	1,346,040	3,184,943	3,044,119
Income (loss) from operations	(373,831)	(358,577)	(812,611)	(202,946)
Other income (expense):				
Interest and dividends, net	(143,931)	(145,095)	(462,919)	(136,007)
Other , net	4,659	7,041	43,851	51,000
Total other income (expense)	(139,272)	(138,054)	(419,068)	(85,007)
Income (loss) from continuing operations before taxes	(513,103)	(496,631)	(1,231,679)	(287,953)
Income tax expense (benefit)	-	-	-	-
Income (loss) from continuing operations	(513,103)	(496,631)	(1,231,679)	(287,953)
Discontinued operations (Note 11)				
Loss from discontinued operations, net of tax	(350,142)	(52,475)	(362,579)	(573,707)
Net loss	\$ (863,245)	\$ (549,106)	\$ (1,594,258)	\$ (861,660)
Net loss per share:				
Basic:				
Income (loss) from continuing operations	\$ (0.06)	\$ (0.06)	\$ (0.15)	\$ (0.04)
Loss from discontinued operations net of tax	(0.04)	(0.01)	(0.04)	(0.07)
Net loss per share	\$ (0.10)	\$ (0.07)	\$ (0.19)	\$ (0.11)
Diluted:				
Income (loss) from continuing operations	\$ (0.06)	\$ (0.06)	\$ (0.15)	\$ (0.04)
Loss from discontinued operations net of tax	(0.04)	(0.01)	(0.04)	(0.07)
Net loss per share	\$ (0.10)	\$ (0.07)	\$ (0.19)	\$ (0.11)
Shares used in computing net loss per share:				
Basic	8,515,824	7,828,322	8,515,824	7,819,072
Diluted	8,515,824	7,828,322	8,515,824	7,819,072

See notes to consolidated financial statements.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)

	Nine months ended	
	September 30,	
	2007	2006
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Loss	\$ (1,594,258)	\$ (861,660)
Adjustments to reconcile net loss to net cash used in operating activities:		
Net loss from discontinued operations	362,579	573,707
Depreciation and amortization	555,213	533,110
Amortization of note valuation discount	323,332	102,956
Bad debt expense (recovery)	(9,301)	(27,789)
Stock option compensation expense	60,645	14,682
Gain on sale of assets	(2,492)	(36,927)
Gain on lease cancellation	(120,755)	-
Realized loss on sale of marketable securities	-	108
Changes in operating assets and liabilities :		
Receivables	45,544	(17,738)
Inventory	214,827	84,487
Other assets	6,358	(27,776)
Accounts payable and accrued expenses	(384,082)	(84,031)
Lease abandonment liability	(27,744)	(56,156)
Deferred compensation	(65,064)	(41,789)
Net operating activities of discontinued operations	146,076	(520,464)
Net cash used in operating activities	(489,122)	(365,280)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of property and equipment	(27,433)	(149,097)
Sales of property and equipment	13,000	84,512
Receipts on notes receivable	1,434	42,060
Purchase of marketable securities, available for sale	-	(1,062,666)
Sales of marketable securities, available for sale	790,393	422,488
Net investing activities of discontinued operations	9,102	43,926
Net cash provided by (used in) investing activities	786,496	(618,777)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Bank overdrafts	-	(203,500)
Net proceeds from issuance of notes	-	1,897,000
Principal payment on capital lease obligations	(86,066)	(62,480)
Deferred financing fees paid	-	(160,000)
Note payable principal payments	(90,875)	-
Net financing activities of discontinued operations	(232,384)	(151,438)
Net cash provided by (used in) financing activities	(409,325)	1,319,582
NET DEC/INC IN CASH AND CASH EQUIVALENTS	(111,951)	335,525
CASH AND CASH EQUIVALENTS, BEGINNING	269,726	118,805
CASH AND CASH EQUIVALENTS, ENDING	157,775	454,330

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Fixed assets acquired through capital lease financing	138,220	178,261
Value of warrants issued to lenders recorded as debt discount	-	588,452
Value of beneficial conversion feature of notes issued recorded as debt discount	-	588,452
Value of warrants issued to advisor recorded as deferred financing costs	-	130,770
Issuance of common stock recorded as deferred financing costs	-	127,500

See notes to consolidated financial statements.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

1. UNAUDITED INTERIM FINANCIAL STATEMENTS

The unaudited consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The accompanying consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company, and notes thereto, for the year ended December 31, 2006.

The information furnished reflects, in the opinion of management, all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the results of the interim periods presented. Operating results of the interim period are not necessarily indicative of the amounts that will be reported for the year ending December 31, 2007.

2. SHARE-BASED COMPENSATION

On January 1, 2006, the Company adopted Statement of Financial Accounting Standards No. 123 (revised 2004), "Share-Based Payment", ("SFAS 123R") which requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors, including employee stock options. SFAS 123R supersedes the Company's previous accounting under Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB 25") for periods beginning in 2006. In March 2005, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 107 ("SAB 107") relating to SFAS 123R. The Company has utilized the guidance of SAB 107 in its adoption of SFAS 123R.

Equity Compensation Plans

During 1995, the Company approved the 1995 Stock Option Plan (the "1995 Plan"), which provides for the grant of (i) nonqualified stock options, (ii) nonqualified stock options with stock appreciation rights attached, (iii) incentive stock options, and (iv) incentive stock options with stock appreciation rights attached. The Company has reserved 1,125,000 shares of the Company's common stock \$.0001 par value (the "Common Stock"), for issuance under the Plan. The Plan limits participation to employees, independent contractors and consultants; however, only employees may be granted incentive stock options under the 1995 Plan. Non-employee directors are excluded from participation in the 1995 Plan. The option price for shares of stock subject to the 1995 Plan is set by the Stock Option Committee of the Board of Directors at a price not less than 85% of the fair market value of the stock on the date of grant in the case of nonqualified stock options and 100% of the fair market value of the stock on the date of grant in the case of incentive stock options. No stock options may be exercised within nine months from the date of grant, unless under a plan exception, nor more than ten years after the date of grant. The 1995 Plan provides for the grant of stock appreciation rights, which allow the holder to receive in cash, stock or combination thereof, the difference between the exercise price and the fair value of the stock at date of exercise. The fair value of stock appreciation rights is charged to compensation expense. The stock appreciation right is not separable from the underlying stock option originally granted and can only be exercised in tandem with the stock option. No stock appreciation rights are attached to any options outstanding. At September 30, 2007, no shares were available for future grants under the 1995 Plan. Outstanding options granted under the 1995 Plan have an exercise price equal to the fair market value on the date of grant, are fully vested at September 30, 2007, and generally expire ten years after grant date.

During 2003, the Company approved the 2003 Stock Incentive Plan (the “2003 Plan”), which provides for the grant of (i) nonqualified stock options, (ii) incentive stock options, and (iii) restricted stock. The Company has reserved 2,000,000 shares of Common Stock for issuance under the 2003 Plan.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

The 2003 Plan limits participation to employees, independent contractors, and consultants; however, only employees may be granted incentive stock options under the 2003 Plan. The option price for shares of stock subject to the 2003 Plan is set by the Compensation Committee of the Board of Directors at a price not less than the fair market value of the Common Stock on the date of grant. No stock options may be exercised within six months from the date of grant, unless under a plan exception, nor more than ten years after the date of grant. At September 30, 2007, no shares were available for future grants under the 2003 Plan. Outstanding options granted under the 2003 Plan have an exercise price equal to the fair market value on the date of grant, are fully vested at September 30, 2007, and generally expire ten years after grant date.

During 2006, the Company approved the 2006 Long-Term Incentive Plan (the "2006 Plan"), which provides for the grant of (i) nonqualified stock options, (ii) incentive stock options, (iii) restricted stock, (iv) stock appreciation rights, and (v) performance units. The Company has reserved 5,000,000 shares of the Company's Common Stock for issuance under the 2006 Plan. The 2006 Plan limits participation to employees and non-employee Directors; however, only employees may be granted incentive stock options under the 2006 Plan. The option price for shares of stock subject to the 2006 Plan is set by the Compensation Committee of the Board of Directors at a price not less than the fair market value of the Common Stock on the date of grant. No stock options may be exercised more than ten years after the date of grant.

Grant-Date Fair Value

The Company uses the Black-Scholes option pricing model to calculate the grant-date fair value of an award. The fair value of options granted during the three and nine months ended September 30, 2007 and 2006 were calculated using the following estimated weighted average assumptions:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2007	2006	2007	2006
Expected volatility	87.88%	77.00%	87.88%	76.10%
Expected term (in years)	5	5	5	5
Risk-free interest rate	4.79%	4.52%	4.79%	4.68%
Expected dividend yield	0%	0%	0%	0%

Expected volatility is based on historical volatility. The expected term of the options is based on management's best estimate. The risk-free interest rate is based on the yield on zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption. The Company has not historically issued any dividends and does not expect to in the future.

Share-Based Compensation Expense

The Company uses the straight-line attribution method to recognize expense for unvested options. The amount of share-based compensation recognized during a period is based on the value of the awards that are ultimately expected to vest. SFAS 123R requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company will re-evaluate the forfeiture rate annually and adjust as necessary.

Share-based compensation expense recognized under SFAS 123R for the three months ended September 30, 2007 and 2006 was \$17,068, and \$9,888, respectively. Share-based compensation expense recognized for the nine months ended September 30, 2007 and 2006 was \$60,645 and \$14,682, respectively.

7

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)***Option Activity*

A summary of the activity under the Company's stock options plans for the nine-month period ended September 30, 2007 is presented below:

	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Options outstanding at December 31, 2006	2,715,009	\$ 2.42		
Granted	300,000	\$ 0.65		\$ 1,000
Exercised	-	-		-
Expired	(104,250)	\$ 0.65		-
Canceled	(50,000)	\$ 1.78		-
Options outstanding at September 30, 2007	2,860,759	\$ 2.28	4.54	\$ 13,000
Option exercisable at September 30, 2007	2,090,759	\$ 2.53	3.91	\$ -
Options vested and options expected to vest at September 30, 2007	2,860,759	\$ 2.28	4.54	\$ -

*The Company's CEO, Jerry Grizzle was granted 250,000 stock options in 2006 as an incentive to join the Company. These options were outside a Company incentive plan.

The total grant-date fair value of stock options that became fully vested during the nine months ended September 30, 2007 was \$60,645. As of September 30, 2007 there was \$256,739 of total unrecognized compensation cost, net of tax and estimated forfeitures, related to unvested share-based awards, which is expected to be recognized over a period of 4.5 years.

3. MARKETABLE SECURITIES

Securities are classified as available for sale with the related unrealized gains and losses excluded from earnings and reported net of income tax as a separate component of stockholders' equity until realized. Realized gains and losses on sales of securities are based on the specific identification method. Declines in the fair value of investment securities below their carrying value that are other than temporary are recognized in earnings.

4. RESTRICTED INVESTMENTS

In connection with the Heartland Cup acquisition, the Company has pledged marketable securities in the amount of \$81,513 as restricted cash against one of the notes payable.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

5.

DEBT

The secured financing consists of the following at September 30, 2007 and December 31, 2006:

	September 30, 2007	December 31, 2006
Laurus term note	\$ 2,000,000	\$ 2,000,000
Partial conversion, issuance of 350,000 shares	(159,125)	(159,125)
Valuation discount	(1,176,904)	(1,176,904)
Accretion of discount to interest expense	451,248	218,791
Total secured financing	\$ 1,115,219	\$ 882,762
Current	\$ 726,664	\$ 257,542
Long-term	\$ 388,555	\$ 625,220

On June 28, 2006, the Company entered into a series of agreements with Laurus Master Fund, Ltd. (“Laurus”) whereby the Company issued to Laurus (i) a secured convertible term note (“Note”) in the principal amount of \$2,000,000, and (ii) a warrant (“Warrant”) to purchase up to 2,272,727 shares of the Company’s common stock at a price of \$0.53 per share. Out of the loan proceeds, the Company agreed to pay the sum of \$74,000 to Laurus Capital Management, LLC, the investment advisor to Laurus, the sum of \$27,500 to Laurus Capital Management, LLC as reimbursement for its due diligence and legal fees and expenses incurred in connection with the transaction, and the sum of \$1,500 to Loeb & Loeb LLP, the escrow agent for Laurus. Total closing costs were \$103,000.

The principal amount of the Note bears interest at a per annum rate equal to the prime rate (as published in the Wall Street Journal from time to time) plus three percent (3.0%); provided, however that the interest rate may not be less than ten percent (10.0%). At September 30, 2007, the interest rate was 10.75%. Under the terms of the Note, interest payments are due monthly beginning July 1, 2006, and principal payments in the amount of \$83,333 are due monthly beginning July 1, 2007. Under the terms of the Note, the monthly payments of interest and/or principal (the “Monthly Amount”) due on the Note are convertible into shares of the Company’s Common Stock at a price of \$0.51 per share, subject to anti-dilution adjustments, if the following criteria are met: (i) the average closing price of the Common Stock for the five (5) days preceding the payment date is greater than or equal to 11.5% of the Fixed Conversion Price (defined below) and (ii) the amount of such conversion does not exceed twenty five percent (25%) of the aggregate dollar trading volume of the Common Stock for the period of 22 trading days immediately preceding such payment date. If subsection (i) above is met but subsection (ii) above is not met as to the entire Monthly Amount, then Laurus is required to convert only such part of the Monthly Amount that meets the criteria of subsection (ii). In October 2006, Laurus converted \$159,125 of principal to Common Stock, effectively delaying the first required principal

payment under the Note to September 1, 2007. The final maturity date of the Note is June 28, 2009 (the "Maturity Date"). Interest expense related to the note was \$54,903 and \$159,027 for the three and nine months ended September 30, 2007, respectively.

The Company has agreed to register all of the shares that are issuable upon conversion of the Note and exercise of the 2,272,727 Warrants. The Company has granted Laurus a right of first refusal with respect to any debt or equity financings.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

The Company calculated that the fair value of the Warrants issued to Laurus was \$588,452 based upon the relative value of the Black-Scholes valuation of the warrants and the underlying debt amount. The Company determined that the beneficial conversion feature (“BCF”) of the Note was \$588,452. The value of the Warrants issued to Laurus of \$588,452 and the \$588,452 of calculated BCF have been reflected by the Company as a valuation discount and offset to the face amounts of the Note. The valuation discount will be amortized into interest expense over the three-year term of the Note using the effective interest method. Amortization of discounts for the conversion feature and the Warrants resulted in charges to interest expense totaling \$93,539 and \$323,332 for the three and nine months ended September 30, 2007, respectively.

In conjunction with the financing, the Company also incurred fees to various investment advisors that facilitated the transaction. These fees totaled \$287,500, of which \$127,500 was paid through the issuance of 250,000 shares of Common Stock. In addition, the Company issued these advisors warrants to purchase 495,543 shares of Common Stock at a price of \$0.51 per share. The Company calculated that the fair value of the Warrants issued to the advisors was \$130,770 based upon the relative value of the Black-Scholes valuation of the Warrants and the underlying debt amount. The closing costs, fees paid to the advisors and the value of the Warrants issued to the advisors have been reflected as deferred financing costs in the accompanying balance sheet and are being amortized over the life of the loan. Amortization of the deferred financing costs related to the Note totaled \$43,439 and \$130,317 for the three and nine months ended September 30, 2007, respectively.

In October 2007, the Company signed an amendment to the previous agreement with Laurus Master Fund, Ltd. The Company and each relevant holder agreed the amount of the principal portion due each month, commencing with the amortization date occurring on October 1, 2007 and ending with the amortization date occurring on January 1, 2008, shall be \$15,000, rather than \$83,333. Monthly payment amounts shall resume pursuant to the Term Note prior to this amendment on February 1, 2008. The aggregate deferred principal payment amount shall be paid in full on the maturity date (as defined in the original Term Note), together with all accrued and unpaid interest and all other amounts due and payable on the maturity date under the original Term Note, the Purchase Agreement and the other Related Agreements referred to in the Purchase Agreement. In addition, the amendment includes the deletion and replacement of the conditions concerning the “Optional Redemption.” The Company may now prepay the Note at any time by paying to the Holder a sum of money equal to 123% of the principal amount outstanding.

6. LOSS PER SHARE

“Loss per common share – basic” is computed based upon net loss divided by the weighted average number of common shares outstanding during each period. “Loss per common share – assuming dilution” is computed based upon net loss divided by the weighted average number of common shares outstanding during each period adjusted for the effect of dilutive potential common shares calculated using the treasury stock method.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

The following is a reconciliation of the common shares used in the calculations of loss per common share – basic and loss per common share – assuming dilution:

	Income (Loss)	Shares	Per
	(Numerator)	(Denominator)	Share
			Amount
Weighted average common shares outstanding:			
For the three months ended September 30, 2007:			
Loss per common share:			
Loss available to common stockholders	\$ (863,245)	8,515,824	\$ (0.10)
Loss per common share – assuming dilution:			
Options	-	-	
Loss available to common stockholders plus assumed conversions	\$ (863,245)	8,515,824	\$ (0.10)
For the three months ended September 30, 2006:			
Loss per common share:			
Loss available to common stockholders	\$ (549,106)	7,828,322	\$ (0.07)
Loss per common share – assuming dilution:			
Options	-	-	
Loss available to common stockholders plus assumed conversions	\$ (549,106)	7,828,322	\$ (0.07)
For the nine months ended September 30, 2007:			
Loss per common share:			
Loss available to common stockholders	\$ (1,594,258)	8,515,824	\$ (0.19)
Loss per common share – assuming dilution:			
Options	-	-	
Loss available to common stockholders plus assumed conversions	\$ (1,594,258)	8,515,824	\$ (0.19)
For the nine months ended September 30, 2006:			

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

Loss per common share:			
Loss available to common stockholders	\$	(861,660)	7,819,072 \$ (0.11)
Loss per common share – assuming dilution:			
Options		-	-
Loss available to common stockholders plus assumed conversions	\$	(861,660)	7,819,072 \$ (0.11)

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

Options to purchase 2,860,759 shares of Common Stock at exercise prices ranging from \$0.51 to \$6.00 per share were outstanding for the three and nine months ended September 30, 2007, but were not included in the computation of income (loss) per common share – assuming dilution because there was a net loss for the period then ended and inclusion of such options is anti-dilutive.

Options to purchase 2,565,009 shares of Common Stock at exercise prices ranging from \$1.30 to \$6.00 per share were outstanding for the three and nine months ended September 30, 2006, but were not included in the computation of income (loss) per common share – assuming dilution because there was a net loss for the period then ended and inclusion of such options is anti-dilutive.

7. DEFERRED TAXES

On a regular basis, management evaluates all available evidence, both positive and negative, regarding the ultimate realization of the tax benefits of its deferred tax assets. Valuation allowances have been established for certain operating loss and credit carryforwards that reduce deferred tax assets to an amount that will, more likely than not, be realized. Uncertainties that may affect the realization of these assets include tax law changes and the future level of product prices and costs. The outlook for determination of this allowance is calculated on the Company's historical taxable income, its expectations for the future based on a rolling twelve quarters, and available tax-planning strategies. Based on this determination, management does not expect that the net deferred tax assets will be realized as offsets to reversing deferred tax liabilities and as offsets to the tax consequences of future taxable income. As such, a valuation allowance was provided for the entire deferred tax asset of approximately \$6,000,000 at September 30, 2007. The Company's effective tax rate differs from its statutory tax rate for the nine months ended September 30, 2007 and 2006, due to the tax valuation allowance. The Company has net operating loss carryforwards of approximately \$14,000,000 available to reduce future taxable income, which will begin to expire in 2021.

8. COMMITMENTS, CONTINGENCIES AND GUARANTEES

Recent Regulatory Developments - As a marketer of products that are ingested by consumers, the Company is subject to the risk that one or more of the ingredients in its products may become the subject of adverse regulatory action. For example, one of the ingredients in the Company's prior AM-300 product was ephedra, an herb that contains naturally-occurring ephedrine alkaloids. The Company's manufacturer used a powdered extract of that herb when manufacturing AM-300. The Company marketed AM-300 principally as an aid in weight management. The extract was an 8% extract, which means that every 100 milligrams of the powdered extract contains approximately eight milligrams of naturally occurring ephedrine alkaloids.

On February 11, 2004, the FDA issued and published in the Federal Register its final rule on ephedrine-containing supplements, stating that since an "unreasonable risk" had been determined, such supplements would be considered "adulterated" under the Federal Food, Drug, and Cosmetic Act, or FFDCFA, and thus may not be sold. In essence, this final rule (or regulation) imposed a national ban on ephedrine supplements. The effective date of this regulation was April 12, 2004. The Company complied with the new regulation and ceased all sales and advertisement of AM-300 and any other ephedra-containing supplement as of April 12, 2004. The FDA has continuously and vigilantly enforced this total ban on ephedra-containing supplements.

For the future, the FDA and also Congress have indicated that they will consider whether alternatives to ephedra, other weight loss and energy stimulants (such as bitter orange), similarly carry an unreasonable risk to the central

nervous system, and thus to human health. These proposals to limit stimulant ingredients, if finalized, may necessitate reformulations of some of the Company's weight loss products.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

Product Liability - Also, in the aftermath of the ephedra ban, on April 22, 2004, in comments before a scientific meeting, then Acting FDA Commissioner, Lester Crawford, outlined what an FDA press release termed a “science-based plan for dietary supplement enforcement”. The press release went on to say that the agency “would soon provide further details about its plan to ensure that the consumer protection provisions of DSHEA are used effectively and appropriately”. Referring to its recent rulemaking on ephedra, the FDA also stated that it “expects to evaluate the available pharmacology, published literature . . . , evidence-based reviews, and adverse event information” of “individual dietary supplements”. Soon afterwards, this promised FDA document was issued, with the title “Regulatory Strategy for the Further Implementation and Enforcement of the Dietary Supplement Health and Education Act of 1994”. No new regulations or proposed rules pursuant to this strategy have yet been issued, except that the FDA has recently welcomed and received comments from the industry for a better procedure for the FDA to review a company’s safety information as to a new dietary ingredient, or NDI, in an NDI Notification. The final guidance document concerning NDI Notifications has not yet been issued by the FDA. At this time, NDI Notifications are not required for any AMS products.

Anti-DSHEA Proposed Legislation. Finally, as the press, the FDA, and members of Congress and of the supplement industry have all predicted, the very issuance of the final rule (ban) on ephedra has caused Congress to rethink the Dietary Supplement Health and Education Act of 1994, or DSHEA, specifically as to how safety in supplements may be ensured, and also as to whether specific categories of dietary ingredients should not be permitted at all. In particular, there is growing sentiment (including from one herbal trade association) to make Adverse Event Reporting (AERs) mandatory for all manufacturers and marketers of dietary supplements, so that the FDA may take action more quickly than it did on ephedra, when a harmful herb or other ingredient is suspected. Since February 2003, there have been several bills proposed in Congress that would amend DSHEA, make safety safeguards stricter, even approaching the rigor and reporting required for FDA-regulated drugs. Some examples are as follows:

S. 722— The Dietary Supplement Safety Act was introduced by Senator Richard Durbin in March 2003, and would greatly undermine DSHEA, especially Section 4 regarding safety, giving the FDA new powers of oversight and blanket authority over whole categories of supplements, including stimulants. Stimulants are used in many weight loss products, including some of our supplements. To the best of our knowledge, this bill and the bill described below (though perhaps under different numbers) are still pending.

H.R. 3377: Beginning on October 28, 2003, Senator McCain chaired Senate Hearings on whether DSHEA adequately protects consumers. Also on October 28, Cong. Susan Davis and Cong. Henry Waxman introduced The Dietary Supplement Access and Awareness Act, H.R. 3377, purporting to be about safety and access for consumers to supplements, but actually recommending severe restrictions and dramatic redefinitions of what constitutes a dietary supplement. This bill would impose several requirements for supplements, including unprecedented FDA pre-approval as well as strict AER reporting, and excludes only vitamins and minerals from such new requirements. Like S. 722, this bill would reverse the safety burden of proof in Section 4 of DSHEA (one of the industry’s victories in 1994), and instead require the manufacturer to demonstrate safety, rather than the burden being on the FDA to show “imminent hazard” or “unreasonable risk”.

So far, neither of the bills above, nor any other proposed legislation that would undermine DSHEA or impose additional requirements on supplements, have passed. The Company will continue to monitor these anti-DSHEA bills, and determine if any of them become a serious threat to our business. In addition, the two major trade associations of the dietary supplement industry—the American Herbal Products Association, or AHPA, and the National Natural Foods Association, or NNFA—have both been actively lobbying against any bills that would require or lead to

unreasonable restraints on the manufacture, labeling, and marketing of dietary supplements.

13

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

Product Liability - AMS, like other marketers of products that are intended to be ingested, face an inherent risk of exposure to product liability claims in the event that the use of their products results in injury. The Company has limited product liability insurance with coverage limits of \$1.0 million per occurrence and \$2.0 million aggregate. All of AMS' product manufacturers carry product liability insurance, which covers the Company's products. Such product claims against the Company could adversely affect product sales, results of their operations, financial condition and the value of common stock.

Legal Proceedings - The Company is currently involved in asserted and unasserted claims, which arise in the ordinary course of business. The Company routinely evaluates whether a loss is probable, and if so, whether it can be estimated. Estimates are based on similar case law matters, consultation with subject matter experts and information obtained through negotiations with counter-parties. As such, accurately depicting the outcome of pending litigation requires considerable judgment and is subject to material differences on final settlement. Accruals for probable losses are recorded in accrued expenses. If the Company's assessment of the probability is inaccurate, the Company may need to record additional accruals or reduce recorded accruals later. In addition, the Company may need to adjust its estimates of the probable loss amounts as further information is obtained or the Company considers settlements. See "Part II, Item 1. Legal Proceedings" for a description of the most significant claims by or against the Company.

Employment Agreements - In January 2006, the Company entered into a written employment agreement with Jerry W. Grizzle, the Company's Chairman of the Board, President and Chief Executive Officer. The contract was originally for a two-year term, commencing January 25, 2006, followed by two successive one-year terms. On April 2, 2007, the Board of Directors extended the Initial Term of Jerry Grizzle's employment agreement from January 25, 2008 to January 25, 2010. Mr. Grizzle's base salary is \$150,000 per year for the first year of the employment agreement, \$200,000 for the second year and \$250,000 for each year thereafter. Additionally, Mr. Grizzle will be eligible to receive certain performance-based incentive bonuses. On February 15, 2006, the Company granted Mr. Grizzle options to purchase 250,000 shares of Common Stock with an exercise price of \$0.62 per share, which was the closing price of the Company's Common Stock on that day. The options vest in five equal annual installments beginning February 15, 2007, and expire February 15, 2016. In the event the Company terminates Mr. Grizzle without cause, he will receive certain severance pay based upon his length of employment with the Company.

In April 2006, the Company entered into a written employment agreement with Robin L. Jacob, the Company's Vice President, Secretary, Treasurer and Chief Financial Officer. The contract is for a two-year term, commencing February 12, 2006, followed by two successive one-year terms unless either party elects not to renew the Agreement. Ms. Jacob's base salary is \$100,000 per year for the first year of her employment agreement, \$112,500 for the second year and \$125,000 for each year thereafter. Additionally, she is eligible to receive certain performance-based incentive bonuses. The Company granted Ms. Jacob options to purchase 150,000 shares of Common Stock at an exercise price of \$0.64 per share, which was the closing price of the Common Stock on March 31, 2006, the last trading day prior to the date the options were granted. The options vest in five equal annual installments beginning April 1, 2007, and expire April 1, 2016. In the event the Company terminates Ms. Jacob without cause, she will receive certain severance pay based upon her length of employment with the Company.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

In September 2006, the Company entered into a written employment agreement with Dennis P. Loney, the Company's Vice President of Operations. The contract is for a two-year term, commencing September 19, 2006, followed by two successive one-year terms unless either party elects not to renew the Agreement. Mr. Loney's base salary is \$106,000 per year for the first year of his employment agreement, \$112,500 for the second year and \$125,000 for each year thereafter. Additionally, he is eligible to receive certain performance-based incentive bonuses. The Company granted Mr. Loney options to purchase 150,000 shares of Common Stock at an exercise price of \$0.63 per share, which was the closing price of the Common Stock on that day. The options vest in five equal annual installments beginning September 19, 2007, and expire September 19, 2016. In the event the Company terminates Mr. Loney without cause, he will receive certain severance pay based upon his length of employment with the Company.

9. DEFERRED COMPENSATION

In connection with the November 4, 2005 extension of Mr. Hail's employment agreement, Mr. Hail's monthly variable salary ceased and was replaced by a fixed supplemental payment, in a gross amount necessary to cover all federal, state, and local taxes and all employment taxes and to pay a net amount of \$7,000 per month.

In 2003, the Company made an accrual for the discounted value of the fixed supplemental payments as a distribution and administrative expense. At September 30, 2007, the discounted value of those fixed supplemental payments was approximately \$312,000. The Company accrues the expense in distribution and administrative expenses. On February 16, 2006, the Company announced Mr. Hail's retirement as Chief Executive Officer and Chairman of the Board.

10. LEASE ABANDONMENT

In January 2004, the Company commenced a relocation of its corporate headquarters from 2601 NW Expressway (the Oil Center), Oklahoma City, Oklahoma to its warehouse and distribution facility. A portion of the Oil Center was maintained for storage, a portion was maintained for possible relocation of Company personnel due to expansion of the business and a portion was subleased to a third party under a short-term lease. In September 2004, the Company purchased an existing building adjacent to its corporate headquarters to be used for additional office, warehouse and storage space. As such, the Company abandoned the Oil Center location. In determining lease abandonment, management assumed the continuation of the existing sublease at the current rate. In addition, a discount rate of 6.5% was used to calculate the present value of current lease payments less sublease revenue. At September 30, 2007, the lease abandonment accrual was approximately \$39,000.

11. DISCONTINUED OPERATIONS

On September 9, 2005 the Company entered into a definitive Stock Purchase Agreement with Heartland Cup, Inc. ("Heartland Cup") and its principal shareholder for the purchase of all of the principal shareholder's stock in Heartland Cup. Upon closing of the Stock Purchase Agreement, the Company acquired 2,000,000 shares, or approximately 83% of the outstanding capital stock of Heartland Cup, for 200,000 shares of the Company's Common Stock. In addition, the Company paid approximately \$200,000 to acquire the remaining shares of Heartland Cup.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

On March 31, 2006, the Company adopted a plan to discontinue the operations of its Heartland Cup subsidiary. On November 15, 2006, the Company entered into certain lease and purchase agreements with Republic Plastics Ltd. (“Republic”) allowing Republic to take over operation of the Heartland Cup plant immediately. Republic produces Styrofoam products for private label users. Pursuant to the agreements, and effective November 15, 2006, Republic assumed the existing lease for the Heartland Cup plant, purchased all remaining cup contracts with Heartland customers, and executed a two-year equipment lease. The equipment lease includes an option in favor of Republic Plastics to purchase all the equipment utilized in the Heartland Cup operations at a specified price. The option period begins November 15, 2007 and ends November 15, 2008. On August 3, 2007 the Company was notified by Republic that they had ceased the operations at Heartland. The Company is currently in negotiations regarding the remaining lease period, and as such, is still evaluating the impact to the Company.

The Company conducted an assessment of the manufacturing equipment listed in the fixed assets of Heartland Cup as of September 30, 2007. As a result, the Company has recorded asset write-downs totaling \$352,598. The Company has contracted with an independent valuation firm to further conduct a valuation of the equipment prior to year-end. At that time any valuation differences will be recorded.

The results of operations of discontinued operations for the three and nine months ended September 30, 2007 and 2006 are summarized below:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2007	2006	2007	2006
Revenues	-	\$ 335,774	\$ 1,931	\$ 1,056,990
Loss from operations of discontinued operations	\$ (350,142)	\$ (52,475)	\$ (362,579)	\$ (553,707)
Estimated cost to sell	-	-	-	(20,000)
Income tax effect	-	-	-	-
Loss from operations of discontinued operations, net of tax	\$ (350,142)	\$ (52,475)	\$ (362,579)	\$ (573,707)

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

The components of assets and liabilities of discontinued operations in the accompanying consolidated balance sheets are as follows:

	September 30, 2007	December 31, 2006
Current assets of discontinued operations:		
Cash	\$ -	\$ 1,252
Accounts Receivable	(1,440)	70,245
Inventory	3,579	39,024
Total	\$ 2,139	\$ 110,521
Noncurrent assets of discontinued operations:		
Other assets	\$ -	\$ 15,431
Property and equipment, net	800,000	1,238,049
Total	\$ 800,000	\$ 1,253,480
Current liabilities of discontinued operations:		
Accounts payable	\$ -	\$ 41,105
Current portion of long-term debt	295,875	296,477
Other current liabilities	20,000	23,000
Total	\$ 315,875	\$ 360,582
Long-term liabilities of discontinued operations:		
Long-term debt	\$ 1,338,576	\$ 1,570,359

In connection with the Heartland acquisition, the Company assumed approximately \$2.1 million in Heartland debt. The loans have varying due dates, interest rates and terms. The loans are collateralized by inventory, furniture and fixtures of Heartland, along with the Company's executive offices and warehouse.

12.**RECENT ACCOUNTING PRONOUNCEMENTS**

In June 2006, the FASB issued interpretation No. 48, Accounting for Uncertainty in Income Taxes—an Interpretation of FASB statement No. 109, (“FIN 48”). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in a company’s financial statements in accordance with SFAS No. 109, Accounting for Income Taxes. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company has evaluated the impact of FIN 48 as of the January 1, 2007 adoption date and determined there will be no impact to its financial statements.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements." SFAS No. 157 clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under SFAS No. 157, fair value measurements would be separately disclosed by level within the fair value hierarchy. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company's management is currently reviewing this new standard to determine its effects, if any, on our financial position, results of operations or cash flows.

In February 2007, the FASB issued SFAS No. 159, which provides entities with an option to report selected financial assets and liabilities at fair value. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. This Statement is effective as of the beginning of the first fiscal year that begins after November 15, 2007. The Company's management is currently evaluating the impact that SFAS No. 159 will have on its consolidated financial statements.

13. CURRENT FINANCIAL CONDITION

Several factors have contributed to the Company's current financial condition:

- The impact of several material non-recurring events, including the one-time impairment of goodwill, the accrual of deferred compensation related to the employment contract of the Company's founder and then CEO, the implementation of a free trial program, the write off of the Company's deferred tax asset, and a lease abandonment charge related to the abandonment of the executive offices;
 - Excessive expenses incurred in the Heartland operations; and
 - Recurring losses due to the FDA's ban on ephedra products.

The Company has taken the following steps to significantly reduce its cost of sales and marketing, distribution and administrative costs:

- Reductions in force, encompassing all departments within the Company;
- The termination of a discount sales program, designed to give customers a cash discount after purchasing a certain dollar amount of product; and
- The termination of several extra employee benefits, including vehicle allowances and social and country-club privileges.

On March 31, 2006, the Company adopted a plan to cease the Heartland operations. The Company included an accrual for discontinued operations in the first quarter of 2006. On November 15, 2006, we entered into certain lease and purchase agreements with Republic Plastics Ltd. allowing Republic to take over operation of the Heartland plant immediately. Republic produces Styrofoam products for private label users. Pursuant to the Agreements, and effective November 15, 2006, Republic assumed the existing lease for the Heartland plant, purchased all remaining cup contracts with Heartland customers, and executed a two-year equipment lease. The equipment lease includes an option in favor of Republic to purchase all the equipment utilized in the Heartland operations at a specified price. The

option period begins November 15, 2007 and ends November 15, 2008. On August 3, 2007 the Company was notified by Republic of cessation of operations at Heartland. The Company is currently in negotiations with Republic concerning the obligations of the lease, and is still evaluating the impact to the Company.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)**

The Company conducted an assessment of the manufacturing equipment listed in the fixed assets of Heartland Cup as of September 30, 2007. As a result, the Company has recorded asset write-downs totaling \$352,598. The Company has contracted with an independent valuation firm to further conduct a valuation of the equipment prior to year-end. At that time any valuation differences will be recorded.

The Company is also exploring strategic acquisitions of network marketing companies with profitable, sustained operations.

In February 2007, the Company introduced a new product offering, SABA, that it believes will be the replacement for the ephedra product banned in 2004.

On June 28, 2006, the Company completed a \$2,000,000 private placement financing through the sale of secured convertible notes to Laurus Master Fund Ltd. The net proceeds of the funding were used primarily for sales and marketing. For a full description of the terms of the note, see Note 5 to Consolidated Financial Statements.

Management believes that a portion of the working capital needs over the next 12 months will be provided by our operating activities and cash and cash equivalents. In order to meet the balance of the Company's working capital requirements, management believes that a refinancing or restructuring of the Company's existing indebtedness will be necessary. The Company has signed a contract with an investment firm to assist us in securing additional working capital.

14. CORRECTION OF ERROR IN REPORTING NET SALES

In the fourth quarter of 2006 it was discovered that the net sales were not being recorded correctly due to an error in system reports. The error was corrected and an adjustment was made in the fourth quarter of 2006. The comparative figures for 2006 have been changed to reflect this correction of error in the financial statements for the three and nine months ended September 30, 2007.

The comparative figures based on the quarterly adjustments in 2006 are as follows:

	2006 Quarters Ended,		
	March 31,	June 30,	September 30,
Net Sales	\$ 2,351,713	\$ 2,397,975	\$ 2,323,583
Adjustment	73,761	82,900	86,668
Adjusted net sales	\$ 2,425,474	\$ 2,480,875	\$ 2,410,251
Net loss from operations as previously reported	\$ (316,314)	\$ (152,900)	\$ (635,774)
Adjusted net loss from operations	\$ (242,553)	\$ (70,000)	\$ (549,106)

15. RECLASSIFICATIONS

Certain reclassifications of the prior year amounts have been made in order to provide comparability with the current presentation. These changes were made for presentation purposes only and did not have any effect on previously reported results of operations or equity.

16. SUBSEQUENT EVENTS

On November 1, 2007, a jury verdict was rendered against the Company in the aggregate amount of \$984,368, relating to breach of contract claims made by the former owner of Heartland Cup, Inc., a company acquired by AMS in 2005. See "Part II, Item 1. Legal Proceedings." The Company does not have the cash resources to satisfy a judgment if entered on the jury's verdict. Additionally, the entry of such a judgment would have material, adverse consequences to the Company in that any such judgment, if not vacated, discharged, stayed or bonded within 30 days of the entry thereof, would constitute an event of default under the terms of the Company's secured convertible note with Laurus. The Company presently is in settlement discussions with Mr. McCarty; pending the outcome of such discussions, no judgment has yet been entered in the matter. Due to the above, the ultimate loss cannot be reasonably estimated; therefore, no liability has been recorded.

Report of Independent Registered Public Accounting Firm

Board of Directors and Stockholders
AMS Health Sciences, Inc. and Subsidiaries

We have reviewed the accompanying consolidated balance sheet of AMS Health Sciences, Inc. and Subsidiaries as of September 30, 2007, and the related consolidated statements of operations and cash flows for the three and nine month periods ended September 30, 2007 and 2006. These financial statements are the responsibility of the Company's management.

We conducted our review in accordance with standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the consolidated financial statements, as of September 30, 2007 and for the three and nine months ended September 30, 2007 and 2006, for them to be in conformity with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of AMS Health Sciences, Inc. and Subsidiaries as of December 31, 2006 and the consolidated statements of operations, stockholders' equity and cash flows for the year then ended (not presented herein) and, in our report dated March 29, 2007, we expressed an unqualified opinion on those statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of December 31, 2006 is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/S/ COLE & REED P.C.

Oklahoma City, Oklahoma
November 19, 2007

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

General

We market a product line consisting of approximately sixty products in three categories; weight management, dietary supplement and personal care products. These products are marketed through a network marketing organization in which independent associates purchase products for resale to retail customers as well as for their own personal use.

On September 9, 2005, we entered into a definitive Stock Purchase Agreement with Heartland and its principal shareholder for the purchase of all of the principal shareholder's stock in Heartland. Upon closing of the Stock Purchase Agreement, we acquired 2,000,000 shares, or approximately 83% of the outstanding capital stock of Heartland, for 200,000 shares of our common stock. In addition, we paid approximately \$200,000 to acquire the remaining shares of Heartland.

As described in Footnote 13 to the Financial Statements, we have made the decision to sell or cease operations at Heartland Cup. As such, our consolidated financial statements reflect Heartland Cup as a discontinued operation. On November 15, 2006, we entered into certain lease and purchase agreements with Republic Plastics Ltd. ("Republic"), allowing Republic to take over operation of the Heartland plant immediately. Republic produces Styrofoam products for private label users. Pursuant to the agreements, and effective November 15, 2006, Republic assumed the existing lease for the Heartland plant, purchased all remaining cup contracts with Heartland customers, and executed a two-year equipment lease. On August 3, 2007 we were notified by Republic of its cessation of operations at Heartland. We are currently in negotiations with Republic concerning its lease obligations, and we are still evaluating the impact to the Company. See "--Liquidity and Capital Resources."

On July 28, 2006, our Chief Executive Officer, outlined a strategic plan for our future operations as follows:

- Sell Heartland Cup.
- Use additional capital to build a foundation that will allow us to grow. Because of our consecutive years of losses, we have not had the funds to develop marketing, training and support tools, and programs to support our independent associates' efforts in the field. On June 28, 2006, we raised \$2,000,000 in additional financing. We used these funds to start an aggressive sales and marketing campaign, which we believe will increase our top line revenues. We intend to produce better product videos, business builder videos, printed material and other materials for use by our independent associates in their marketing efforts. In addition we intend to upgrade our back office to provide our independent associates with the most current management tools available in network marketing.
- Establish a new binary commission system and allow our independent associates to choose to use our existing commission system or the new binary commission system depending on their primary method of generating revenues. This will allow our independent associates to tailor their commission system to their operating methods.
- Enter the international markets.

In February 2007, we launched a new division, Saba, that included a new binary commission system, allowing associates to choose the existing commission system or the new binary system. We also introduced new product and business builder videos and printed materials for use by our independent associates in their marketing efforts. We have also upgraded our back office to provide associates with the most current management tools.

We have received a comment letter from the SEC related to our December 31, 2006 Form 10-KSB and our June 30, 2007 Form 10-QSB. We are evaluating the comments and will respond to them in a timely manner, as set forth in the original letter.

Critical Accounting Policies

We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States, which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Actual results could differ from those estimates. We consider the following policies to be most critical in understanding the judgments that are involved in preparing our financial statements and the uncertainties that could impact our results of operations, financial condition and cash flows.

Throughout this report, “net sales” represents the gross sales amounts reflected on our invoices to our associates, less associate discounts and sales returns. All of our products include a customer satisfaction guarantee. Our products may be returned within 30 days of purchase for a full refund or credit toward the purchase of another product. We also have a buy-back program whereby we repurchase products sold to an independent associate (subject to a restocking fee), provided the associate terminates his/her associateship agreement with us and returns the product within 12 months of original purchase in marketable condition. We receive our net sales price in cash or through credit card payments upon receipt of orders from associates.

Our “gross profit” consists of net sales less:

- Commissions and bonuses, consisting of commission payments to associates based on their current associate level within their organization, and other one-time incentive cash bonuses to qualifying associates;
- Cost of products, consisting of the prices we pay to our manufacturers for products, and royalty overrides earned by qualifying associates on sales within their associate organizations; and
- Cost of shipping, consisting of costs related to shipments, duties and tariffs, freight expenses relating to shipment of products to associates and similar expenses.

We recognize revenue upon shipment of products, training aids and promotional material to our independent associates. All of our customers pay for sales in advance of shipment. As such, we have no trade receivables. Previously, we provided financing to associates, with associate loans repayable in five years or less, and which were secured by commissions controlled by us. Associate loans are no longer allowed. Interest rates on loans were typically two percent or more above the Prime rate and were fixed. All loans were secured by guaranteed payment sources that were within our control, but subject to increases and decreases depending upon associate sales activity. Management determined that there was a possibility of default on the associate loans. As such, we have reserved an allowance for doubtful accounts in connection with the associate loans. At September 30, 2007, the allowance was approximately \$109,000. Total associate loans still outstanding at September 30, 2007 totaled approximately \$143,500.

In July 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 142, “Goodwill and Other Intangible Assets”. This standard requires companies to stop amortizing existing goodwill and intangible assets with indefinite lives effective January 1, 2002. Under the new rules, companies would only adjust the carrying amount of goodwill or indefinite life intangible assets upon an impairment of the goodwill or indefinite life intangible assets. Our intangible assets consist of non-compete covenants and other intangibles, which have a significant residual value. These intangible assets are being amortized over the life of the contracts. We evaluate all intangible assets annually for indicators of impairment.

We use an asset and liability approach to account for income taxes. Deferred income taxes are recognized for the tax consequences of temporary differences and carryforwards by applying enacted tax rates applicable to future years to differences between the financial statement amounts and the tax bases of existing assets and liabilities. A valuation allowance is established if, in management's opinion, it is more likely than not that some portion of the deferred tax

asset will not be realized. All evidence, both positive and negative, is considered to determine whether a valuation allowance is needed for some or all of a deferred tax asset. Judgment must be used in considering the relative impact of negative and positive evidence. The more negative evidence that exists, (a) the more positive evidence is necessary and (b) the more difficult it is to support a conclusion that a valuation allowance is not needed. Based on the above factors and management's evaluation, we determined at December 31, 2004, that a valuation allowance should be established for our entire deferred tax asset, which was approximately \$6,000,000 at September 30, 2007.

22

We write down our inventory to provide for estimated obsolete or unsalable inventory based on assumptions about future demand for our products and market conditions. If future demand and market conditions are less favorable than management's assumptions, additional inventory write-downs could be required. Likewise, favorable future demand and market conditions could positively impact future operating results if written-off inventory is sold. At September 30, 2007, we had a marketing inventory obsolescence reserve of approximately \$41,000 for estimated obsolete or unsalable inventory.

We account for contingencies in accordance with SFAS No. 5, "Accounting for Contingencies". SFAS 5 requires that we record an estimated loss from a loss contingency when information available prior to issuance of our financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and income tax matters requires us to use our judgment. Many legal and tax contingencies can take years to resolve. Generally, as the time period increases over which the uncertainties are resolved, the likelihood of changes to the estimate of the ultimate outcome increases. However, an adverse outcome in these matters could have a material impact on our results of operations, financial condition and cash flows.

Results of Operations

The following table sets forth, in dollars and as a percentage of net sales, selected results of operations for the three and nine months ended September 30, 2007 and 2006. The selected results of operations are derived from our unaudited consolidated financial statements. The results of operations for the periods presented are not necessarily indicative of our future operations.

[REST OF THIS PAGE INTENTIONALLY LEFT BLANK]

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

	For the Three Months Ended				For the Nine Months Ended			
	September 30,				September 30,			
	2007		2006		2007		2006	
	Amount	Percent	Amount	Percent	Amount	Percent	Amount	Percent
Net sales	\$ 1,706,402	100.0%	\$ 2,410,251	100.0%	\$ 6,121,032	100.0%	\$ 7,316,600	100.00%
Cost of Sales:								
Commissions and bonuses	489,291	28.7	793,570	32.9	1,884,863	30.8	2,353,968	32.2
Cost of products	412,655	24.2	298,023	12.4	1,205,007	19.7	1,219,027	16.7
Cost of shipping	189,776	11.1	331,195	13.7	658,830	10.8	902,432	12.3
Total cost of sales	1,091,722	64.0	1,422,788	59.0	3,748,700	61.3	4,475,427	61.2
Gross profit	614,680	36.0	987,463	41.0	2,372,332	38.7	2,841,173	38.8
Marketing and administrative expenses:								
Marketing	106,587	6.2	211,127	8.8	489,114	8.0	454,122	6.2
Administrative	881,924	51.7	1,134,913	47.1	2,695,829	44.0	2,589,997	35.4
Total marketing and administrative expenses	988,511	57.9	1,346,040	55.9	3,184,943	52.0	3,044,119	41.6
Loss from operations	(373,831)	(21.9)	(358,577)	(14.9)	(812,611)	(13.3)	(202,946)	(2.8)
Other income (expense):								
Interest and dividends, net	(143,931)	(8.4)	(145,095)	(6.0)	(462,919)	(7.5)	(136,007)	(1.9)
Other income (expense)	4,659	0.3	7,041	0.2	43,851	0.7	51,000	0.7
Total other income (expense)	(139,272)	(8.1)	(138,054)	(5.8)	(419,068)	(6.8)	(85,007)	(1.2)
Loss from continuing operations before taxes	(513,103)	(30.0)	(496,631)	(20.6)	(1,231,679)	(20.1)	(287,953)	(4.0)
Income tax	-	-	-	-	-	-	-	-
Loss from continuing operations	(513,103)	(30.0)	(496,631)	(20.6)	(1,231,679)	(20.1)	(287,953)	(4.0)
Discontinued operations:								
Loss from operations of Heartland Cup	(350,142)	(20.5)	(52,475)	(2.2)	(362,579)	(5.9)	(573,707)	(7.8)
Income tax benefit	-	-	-	-	-	-	-	-
Total loss from discontinued	(350,142)	(20.5)	(52,475)	(2.2)	(362,579)	(5.9)	(573,707)	(7.8)

operations

Net loss	\$ (863,245)	(50.5)%	\$ (549,106)	(22.8)%	\$ (1,594,258)	(26.0)%	\$ (861,660)	(11.8)%
----------	--------------	---------	--------------	---------	----------------	---------	--------------	---------

Comparison of the Three Months ended September 30, 2007 and 2006

Our net sales during the three months ended September 30, 2007 decreased \$703,849 or 29.2%, to \$1,706,402 from \$2,410,251 during the three months ended September 30, 2006. Due to the correction of an error, the net sales for the three months ended September 30, 2006 increased by \$86,668 from \$2,323,583 to \$2,410,251. See Part I, Note 14 for a description of the reported change.

In late February 2007, we launched a new division and product. Saba weight loss features the Borojo fruit, a fruit which offers essential amino acids for the body, as well as our exclusive formula of adaptogens, which help

diminish the impact of physical, mental and emotional stress. Saba weight loss accounted for approximately \$698,000 of net sales for the three months ended September 30, 2007.

Our cost of sales during the three months ended September 30, 2007 decreased \$331,066, or 23.3%, to \$1,091,722 from \$1,422,788 during the same period in 2006. Total cost of sales, as a percentage of net sales, increased to 64.0% during the three months ended September 30, 2007 from 59.0% during the same period in 2006. The decrease in cost of sales resulted from:

- A decrease of approximately \$304,000 in associate commissions and bonuses;
- An increase of approximately \$115,000 in cost of products due to inventory adjustments related to obsolete products; and
- A decrease of approximately \$141,000 in the costs of shipping.

The factors discussed above resulted in a decrease in gross profit of \$372,783, or 37.8%, to \$614,680 for the three months ended September 30, 2007 from \$987,463 for the same period in 2006.

Marketing expenses decreased \$104,540, or 49.5%, to \$106,587 during the three months ended September 30, 2007, from \$211,127 during the same period in 2006. The decrease in expense was primarily attributable to:

- A decrease in employee costs of approximately \$9,000 related to reductions in staff;
- A decrease in promotional cost of approximately \$56,000 related to spending for the AMS National Convention;
- A decrease in professional services of approximately \$27,000 related to less consultant utilization; and
- A decrease in general and administrative expense of approximately \$6,000.

Administrative expenses decreased \$252,989 or 22.3%, to \$881,924 during the three months ended September 30, 2007 from \$1,134,913 during the same period of 2006. The decrease in expense was primarily attributable to:

- A decrease in employee costs of approximately \$35,000 related reductions in staff;
- A decrease in shareholder relations expense of approximately \$37,000 primarily related to a change in investor relation firms;
- A decrease in professional services of approximately \$85,000 related primarily to consulting services;
- A decrease in promotional expenses of approximately \$29,000 primarily related to the change in IT software used;
- A decrease in rent and insurance expense of approximately \$42,000 primarily related to adjustments made to the lease abandonment accrual; and
- A decrease in depreciation and amortization expense of approximately \$37,000 primarily related to a correction made for the depreciation of the non-competes.

The decrease in administrative expense was partially offset by an increase in vehicle and equipment expense of approximately \$4,000.

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

The marketing and administrative expenses as a percentage of net sales increased to 57.9% during the three months ended September 30, 2007 from 55.9% during the same period in 2006.

Our net other expense (reduced by other income) increased by \$1,218 to net other expense of \$139,272 at September 30, 2007, from net other expense of \$138,054 during the same period in 2006, primarily due to:

- A decrease in interest expense of approximately \$13,000 related to the Laurus debt; and
- An increase in gain on sale of assets of approximately \$6,000 related to the sale of an excess vehicle;

The increase in interest expense was partially offset by:

- A decrease in other income of approximately \$7,000 related to the reduced collection of notes receivable previously written off; and
- A decrease in income of approximately \$10,000 related to the collection of notes receivable interest;

Our net loss from continuing operations increased \$16,472 to net loss of \$513,103 for the three months ended September 30, 2007, from net loss of \$496,631 for the same period in 2006. This decrease was attributable to:

- The decrease in gross profit to \$614,680 during 2007 from \$987,463 during 2006;
- The decrease in marketing and administrative expenses to \$988,511 during 2007 from \$1,346,040 during 2006; and
- The increase in other expense to \$139,272 during 2007 from \$138,054 during 2006.

Net loss from continuing operations as a percentage of net sales increased to 30.0% for the three months ended September 30, 2007, from 20.6% during the same period in 2006.

Net loss increased \$314,139 to \$863,245 for the three months ended September 30, 2007, compared to \$549,106 for the same period of 2006.

Comparison of the Nine Months ended September 30, 2007 and 2006

Our net sales during the nine months ended September 30, 2007 decreased \$1,195,568 or 16.3%, to \$6,121,032 from \$7,316,600 during the nine months ended September 30, 2006. Due to the correction of an error, the net sales for the nine months ended September 30, 2006 increased by \$243,329 from \$7,073,271 to \$7,316,600. See Part I, Note 14 for a description of the reported change.

In late February 2007, we launched a new division and product. Saba weight loss features the Borojo fruit, a fruit which offers essential amino acids for the body, as well as our exclusive formula of adaptogens, which help diminish the impact of physical, mental and emotional stress. Saba weight loss accounted for approximately \$1,342,258 of net sales for the nine months ended September 30, 2007.

Our cost of sales during the nine months ended September 30, 2007 decreased \$726,727, or 16.2%, to \$3,748,700 from \$4,475,427 during the same period in 2006. Total cost of sales, as a percentage of net sales, increased to 61.3% during the nine months ended September 30, 2007 from 61.2% during the same period in 2006. The decrease in cost of sales resulted from:

- A decrease of approximately \$469,000 in associate commissions and bonuses;

- A decrease of approximately \$14,000 in cost of products; and
- A decrease of approximately \$244,000 in shipping costs.

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

The factors discussed above resulted in a decrease in gross profit of \$468,841, or 16.5%, to \$2,372,332 for the nine months ended September 30, 2007 from \$2,841,173 for the same period in 2006.

Marketing expenses increased \$34,992, or 7.7%, to \$489,114 during the nine months ended September 30, 2007, from \$454,122 during the same period in 2006. The increase in expense was primarily attributable to:

- An increase in promotional cost of approximately \$24,000, related primarily to the 2007 national convention; and
- An increase in professional services of approximately \$110,000 related to consulting fees for the branding of the new SABA division.

The increase in marketing expense was partially offset by:

- A decrease in general and administrative expense of approximately \$2,000 related to postage, supplies, telephone, etc.;
- A decrease in employee costs of approximately \$44,000 related to reductions in staff; and
- A decrease in travel costs of approximately \$6,000 related to outside travel of marketing.

Administrative expense increased \$105,832 or 4.1%, to \$2,695,829 during the nine months ended September 30, 2007 from \$2,589,997 during the same period of 2006. The increase in expense was primarily attributable to:

- An increase in employee costs of approximately \$78,000 related primarily to the option expense under FAS 123R and employee vacation liability adjustment;
- An increase in shareholder relations expense of approximately \$20,000 related to AMEX fee;
- An increase in vehicle, equipment, and building expense of approximately \$8,000 related to repairs and maintenance costs;
- An increase in general and administrative expense of approximately \$56,000 related to postage, supplies, telephone, etc.; and
- An increase in rent and insurance expenses of approximately \$6,000 related to corrections of the lease abandonment accrual and the addition of director and officer liability insurance.

The increase in administrative expense was partially offset by:

- A decrease in professional services of approximately \$84,000 related primarily to consulting services;
- A decrease in travel expense of approximately \$13,000 related primarily to reduction in staff and outside travel; and
- A decrease in promotional expenses of approximately \$8,000 related to reduced website expenses.

The marketing and administrative expenses as a percentage of net sales increased to 52.0% during the nine months ended September 30, 2007 from 41.6% during the same period in 2006.

Our net other expense (reduced by other income) increased by \$334,061 to net other expense of \$419,068 at September 30, 2007, from net other expense of \$85,007 during the same period in 2006, primarily due to:

- A decrease in gain on sale of assets of approximately \$34,000 related to the sale of assets in 2006;
- An increase in interest expense of approximately \$326,000 related to the Laurus debt executed in 2006; and

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

- An increase in Sales Tax Discount expense of approximately \$3,000.

The increase in net other expense was partially offset by:

- An increase in gain on sale of marketable securities of approximately \$14,000; and
- An increase in other income of approximately \$17,000 related to the collection of notes receivable previously written off.

Our net loss from continuing operations increased \$943,726 to net loss of \$1,231,679 for the nine months ended September 30, 2007, from net loss of \$287,953 for the same period in 2006. This increase was attributable to:

- The decrease in gross profit to \$2,372,332 during 2007 from \$2,841,173 during 2006;
- The increase in marketing and administrative expense to \$3,184,943 during 2007 from \$3,044,119 during 2006; and
- The increase in other expense to \$419,068 during 2007 from \$85,007 during 2006.

Net loss from continuing operations as a percentage of net sales increased to 20.1% for the nine months ended September 30, 2007, from 3.9% during the same period in 2006.

Net loss increased \$656,828 to \$1,518,488 for the nine months ended September 30, 2007, compared to \$861,660 for the same period of 2006. This increase was primarily the result of the factors discussed above.

Seasonality

No pattern of seasonal fluctuations exists due to the patterns that we are currently experiencing. However, there is no assurance that we will not become subject to seasonal fluctuations in operations.

Recently Issued Accounting Standards

In June 2006, the FASB issued interpretation No. 48, Accounting for Uncertainty in Income Taxes—an Interpretation of FASB statement No. 109, (“FIN 48”). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in a company’s financial statements in accordance with SFAS No. 109, Accounting for Income Taxes. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company has evaluated the impact of FIN 48 as of the January 1, 2007 adoption date and determined there will be no impact to its financial statements.

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements.” SFAS No. 157 clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under SFAS No. 157, fair value measurements would be separately disclosed by level within the fair value hierarchy. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company’s management is currently reviewing this new standard to determine its effects, if any, on our financial position, results of operations or cash flows.

In February 2007, the FASB issued SFAS No. 159, which provides entities with an option to report selected financial assets and liabilities at fair value. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. This Statement is effective as of the beginning of the first fiscal year that begins after November 15,

2007. The Company's management is currently evaluating the impact that SFAS No. 159 will have on its consolidated financial statements.

28

Liquidity and Capital Resources

Our primary source of liquidity has been cash provided by sales of our common stock and marketable securities. At September 30, 2007, we had a working capital deficit of (\$1,478,361), compared to a working capital deficit of (\$252,426) at December 31, 2006. Our working capital needs over the next 12 months consist primarily of marketing and administrative expenses and debt service requirements. As discussed below and in Note 5 of the Notes to the Consolidated Financial Statements, beginning on September 1, 2007, we were required to begin making principal payments on the Laurus debt in the amount of \$83,333 per month, in addition to the monthly payments of interest that we had been making since July 2006. If certain criteria are met, Laurus is required under the terms of the Note to convert the principal and interest payments into share of our common stock, at a price of \$0.51 per share, with no effect on cash flow. To the extent that such conditions are not met, however, or are only partially met, we would be required to make the payments of principal and interest, or some portion thereof, in cash. Additionally, certain restrictions exist on Laurus' ability to convert the Note into our common stock. Most importantly, Laurus is prohibited from converting the Note or exercising its Warrant if such conversion would result in Laurus beneficially owning more than 4.99% of our common stock. Laurus can waive this restriction upon 61 days' notice to us. Additionally, this restriction becomes automatically null and void upon an event of default under the Note.

In October 2007, the Company and Laurus amended the Note to defer a portion of the principal otherwise due under the Note, commencing with the amortization date occurring on October 1, 2007 and ending with the amortization date occurring on January 1, 2008 (the "Deferral Period"), so that the principal payment payable to Laurus for each of the four months during the Deferral Period shall be \$15,000, rather than the \$83,333 provided under the terms of the Note. The aggregate deferred principal payment amounts are due in full on the maturity date (as defined in the original Term Note), together with all accrued and unpaid interest and all other amounts due and payable on the maturity date under the original Term Note, the Purchase Agreement and the other Related Agreements referred to in the Purchase Agreement. In addition, the amendment includes the deletion and replacement of the conditions concerning Optional Redemption. The Company may now prepay the Note at any time by paying to the holder a sum of money equal to 123% of the principal amount outstanding. As discussed in the following paragraph, the Company is working with its financial adviser to obtain financing to prepay the Note prior to the end of the Deferral Period.

On March 31, 2006, we adopted a plan to cease the Heartland operations. We included an accrual for discontinued operations in the first quarter of 2006. On November 15, 2006, we entered into certain lease and purchase agreements with Republic Plastics Ltd. allowing Republic to take over operation of the Heartland plant immediately. Republic produces Styrofoam products for private label users. Pursuant to the Agreements, and effective November 15, 2006, Republic assumed the existing lease for the Heartland plant, purchased all remaining cup contracts with Heartland customers, and executed a two-year equipment lease. The equipment lease includes an option in favor of Republic to purchase all the equipment utilized in the Heartland operations at a specified price. The option period begins November 15, 2007 and ends November 15, 2008. On August 3, 2007 we were notified by Republic of its cessation of operations at Heartland. We are currently in negotiations with Republic concerning its lease obligations, and we are still evaluating the impact to the Company. However, we have conducted an assessment of the manufacturing equipment listed in the fixed assets of Heartland Cup as of September 30, 2007. As a result, we have recorded asset write-downs totaling \$352,598. We have contracted with an independent valuation firm to further conduct a valuation of the equipment prior to year-end. At that time the valuation differences will be recorded.

On November 1, 2007, a jury verdict was rendered against us in the aggregate amount of \$984,368, relating to breach of contract claims made by the former owner of Heartland Cup, Inc., a company acquired by AMS in 2005. See "Part II, Item 1. Legal Proceedings." The Company does not have the cash resources to satisfy a judgment if entered on the jury's verdict. Additionally, the entry of such a judgment would have material, adverse consequences to the Company in that any such judgment, if not vacated, discharged, stayed or bonded within 30 days of the entry thereof, would constitute an event of default under the terms of the Company's secured convertible note with Laurus. We presently are in settlement discussions with Mr. McCarty; pending the outcome of such discussions, no judgment has yet been entered in the matter.

Management believes that a portion of the working capital needs over the next 12 months will be provided by our operating activities and cash and cash equivalents. In order to meet the balance of the Company's working capital requirements, management believes that a refinancing or restructuring of the Company's existing indebtedness will be necessary. We have signed a contract with an investment firm to assist us in securing

29

additional working capital. During the nine months ended September 30, 2007, net cash used in operating activities was (\$489,122), net cash provided by investing activities was \$786,496 and net cash used in financing activities was (\$409,325). This represented a net decrease in cash during the period of \$111,951. We are also exploring strategic acquisitions of network marketing companies with profitable, sustained operations.

The following have contributed to our current cash and cash equivalent position:

- Excessive expenses incurred in the Heartland operations. We estimate that we have incurred approximately \$1.5 million in additional expenses related to the operations of Heartland Cup that we did not anticipate at the time of the acquisition. Additionally, we suffered a loss of approximately \$574,000 in 2006 in connection with the Heartland Cup operations.
- Recurring losses due to the FDA's ban on ephedra products. Because of the ban, the Company was forced to cease sales of AM-300, its primary revenue-generating product containing ephedra. In 2003, our revenue from ephedra-based products was approximately \$6.5 million, only \$728,000 in 2004, and \$0 after that. While we have introduced a replacement product line, known as SABA, revenues from sales of the replacement product line have not yet reached the levels of AM-300 sales prior to the ephedra ban.

We have taken the following steps to significantly reduce our cost of sales and marketing, distribution and administrative costs:

- Reductions in force, encompassing all departments within the Company;
- The termination of a discount sales program, designed to give customers a cash discount after purchasing a certain dollar amount of product; and
- The termination of several extra employee benefits, including vehicle allowances and social and country-club privileges

In October 2007, the Company signed an amendment to the previous agreement with Laurus Master Fund, Ltd. The Company and each relevant holder agreed the amount of the principal portion due each month, commencing with the amortization date occurring on October 1, 2007 and ending with the amortization date occurring on January 1, 2008, shall be \$15,000, rather than \$83,333. Monthly payment amounts shall resume pursuant to the Term Note prior to this amendment on February 1, 2008. The aggregate deferred principal payment amount shall be paid in full on the maturity date (as defined in the original Term Note), together with all accrued and unpaid interest and all other amounts due and payable on the maturity date under the original Term Note, the Purchase Agreement and the other Related Agreements referred to in the Purchase Agreement. In addition, the amendment includes the deletion and replacement of the conditions concerning the "Optional Redemption." The Company may now prepay the Note at any time by paying to the Holder a sum of money equal to 123% of the principal amount outstanding.

Item 3. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, an evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as required by Rule 13a-15(b). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective. There have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

On February 6, 2006, AMS Health Sciences, Inc. and AMS Manufacturing, Inc. filed a lawsuit against Truett McCarty. *AMS Health Sciences, Inc. and AMS Manufacturing, Inc. v. Truett McCarty*, District Court of Oklahoma County, State of Oklahoma, Case No. CJ-2006-981. We alleged that Mr. McCarty defrauded us in the sale of his stock in Heartland by failing to disclose the true amount of Heartland's accounts payable and a certain long-term liability of Heartland. In addition, we alleged that this failure was a breach of the stock purchase agreement Mr. McCarty signed with us. Mr. McCarty filed an answer denying our allegations. In addition, Mr. McCarty alleged several counterclaims against us. Mr. McCarty alleged we defrauded him with regard to the value of the stock he received in exchange for his interest in Heartland, that we breached the terms of the stock purchase agreement by failing to take steps to remove Mr. McCarty as guarantor of certain promissory notes, that we tortiously interfered with a promissory note between Mr. McCarty and Heartland and that we tortiously interfered with an employment agreement between Mr. McCarty and Heartland. Mr. McCarty sought punitive damages on these claims. Mr. McCarty also sought to reform the stock purchase agreement in numerous respects, and to pierce the corporate veils of AMS Health Sciences, Inc. and AMS Manufacturing, Inc. in order to hold them liable for any breach by Heartland of the promissory note and employment agreement between Heartland and Mr. McCarty. In addition, Mr. McCarty brought claims against Heartland for breach of the promissory note and employment agreement. We denied liability to Mr. McCarty and vigorously defended these counterclaims. On July 31, 2007, the Court entered summary judgment in favor of the AMS entities on McCarty's fraud claim against them.

A jury trial began on October 29, 2007, and on November 1, 2007, the jury returned its verdict. The jury found in favor of Mr. McCarty on our claims against him. In addition, the jury found in Mr. McCarty's favor on his claim against us for breach of the stock purchase agreement and found that Mr. McCarty was entitled to \$800,000. In addition, the jury found that Heartland had breached the employment agreement with Mr. McCarty and found that Mr. McCarty was entitled to \$368. The jury also found that Heartland breached its promissory note with Mr. McCarty and that Mr. McCarty was entitled to \$184,000. The jury found that the corporate veils of AMS Health Sciences, Inc., AMS Manufacturing, Inc. and Heartland Cup, Inc. should be pierced. The court allowed the jury to consider a fraud claim by Mr. McCarty against the AMS entities, even though the court had previously granted summary judgment in favor of the AMS entities on McCarty's fraud claim against them. The jury found for Mr. McCarty on the fraud claim, but did not award any additional actual damages for the claim. The jury returned a verdict in our favor on Mr. McCarty's claim for tortious interference and to reform the stock purchase agreement and awarded Mr. McCarty no damages on his claim against us for fraud. Although the jury found that the AMS entities had committed conduct which would warrant the award of punitive damages, if any, to be awarded, Mr. McCarty withdrew his request for punitive damages.

As discussed elsewhere in this Report, we do not have the cash resources to satisfy a judgment if entered on the jury's verdict. Additionally, the entry of such a judgment would have material, adverse consequences to the Company in that any such judgment, if not vacated, discharged, stayed or bonded within 30 days of the entry thereof, would constitute an event of default under the terms of the Company's secured convertible note with Laurus. We presently are in settlement discussions with Mr. McCarty; pending the outcome of such discussions, no judgment has yet been entered in the matter. See "Part I, Item 2. Management's Discussion and Analysis or Plan of Operations—Liquidity and Capital Resources."

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

Item 3. DEFAULTS UPON SENIOR SECURITIES

None

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

Item 5. OTHER INFORMATION

On September 4, 2007, the Company was notified by the AMEX of its affirmation of the determination to delist the common stock of the Company, in accordance with Sections 1003(a)(i), (ii) and (iii) of the AMEX Company Guide. The notice provided that the AMEX would (1) suspend trading in the Company's common stock as soon as practicable, i.e., after the 15 calendar-day period following the September 4, 2007 date of the written notice, during which the Company could file a written appeal of the hearing panel's decision, and (2) file as soon as practicable an application with the Securities and Exchange Commission ("SEC") to strike the Company's common stock from listing and registration on the AMEX. On September 19, 2007, before the market open, the AMEX suspended trading on the exchange of the Company's common stock under the ticker symbol "AMM." At the market open on such date, the Company's common stock commenced quotation on the Over-the-Counter Market (OTCBB) under the symbol "AMSI."

32

Item 6. EXHIBITS

(a) Exhibits

- 3.1 The Registrant's Certificate of Incorporation, incorporated by reference to the Registration Statement on Form SB-2 (Registration No. 333-47801) filed with the Commission on March 11, 1998.
- 3.2 The Registrant's Bylaws, incorporated by reference to the Registration Statement on Form SB-2 (Registration No. 333-47801) filed with the Commission on March 11, 1998.
- 10.1 Stock Option Agreement of Advantage Marketing Systems dated January 3, 2001, incorporated by reference to Form 8-K filed with the Commission on January 8, 2001.
- 10.2* The Advantage Marketing Systems, Inc. 1995 Stock Option Plan, incorporated by reference to Form SB-2 Registration Statement (No. 33-80629), filed with the Commission on November 20, 1996.
- 10.3* Employment Agreement by and between Steven G. Kochen and Registrant dated effective as of August 9, 2005, incorporated by reference to Form 8-K filed with the Commission on August 12, 2005.
- 10.4* Employment Agreement by and between Jerry W. Grizzle and Registrant dated effective as of January 25, 2006, incorporated by reference to Form 10-KSB filed with the Commission on April 3, 2006.
- 10.5* Employment Agreement by and between Robin L. Jacob and Registrant dated effective as of February 12, 2006, incorporated by reference to Form 8-K filed with the Commission on April 12, 2006.
- 10.6 Consulting Agreement by and between TVC Consulting and Registrant dated effective as of March 1, 2006, incorporated by reference to Form 10-QSB filed with the Commission on May 15, 2006
- 10.7 Securities Purchase Agreement dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.8 Secured Convertible Term Note dated June 28, 2006 by the Company in favor of Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.9 Common Stock Purchase Warrant dated June 29, 2006 by the Company in favor of Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.10 Registration Rights Agreement dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.11 Stock Pledge Agreement dated June 28, 2006 by and among the Company, AMS Manufacturing, Inc. and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.12 Master Security Agreement dated June 28, 2006 by and among the Company, AMS Manufacturing, Inc. and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.13 Mortgage dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.14 Grant of Security Interest in Patents and Trademarks dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

33

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

10.15 Common Stock Purchase Warrant dated June 28, 2006 by the Company in favor of Ascendant Securities, LLC, incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.16 Engagement Letter between the Company and Ascendant Securities, LLC, incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.17* Employment Agreement by and between Dennis P. Loney and Registrant dated effective as of September 19, 2006, incorporated by reference to Form 8-K filed with the Commission on September 25, 2006.

15 Letter of independent accountants as to unaudited interim financial information, filed herewith.

31.1 Chief Executive Officer Certification, filed herewith.

31.2 Chief Financial Officer Certification, filed herewith.

32.1 Section 1350 Certification of our Chief Executive Officer, filed herewith.

32.2 Section 1350 Certification of our Chief Financial Officer, filed herewith.

* Designates a compensatory plan.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

REGISTRANT:
AMS HEALTH SCIENCES, INC.

Dated: November 19, 2007

By: /S/ ROBIN L. JACOB
Robin L. Jacob, Vice President and
Chief
Financial Officer
(Duly Authorized Officer of Registrant
and
Principal Financial Officer)

Index of Exhibits

- 3.1 The Registrant's Certificate of Incorporation, incorporated by reference to the Registration Statement on Form SB-2 (Registration No. 333-47801) filed with the Commission on March 11, 1998.
- 3.2 The Registrant's Bylaws, incorporated by reference to the Registration Statement on Form SB-2 (Registration No. 333-47801) filed with the Commission on March 11, 1998.
- 10.1 Stock Option Agreement of Advantage Marketing Systems dated January 3, 2001, incorporated by reference to Form 8-K filed with the Commission on January 8, 2001.
- 10.2* The Advantage Marketing Systems, Inc. 1995 Stock Option Plan, incorporated by reference to Form SB-2 Registration Statement (No. 33-80629), filed with the Commission on November 20, 1996.
- 10.3* Employment Agreement by and between Steven G. Kochen and Registrant dated effective as of August 9, 2005, incorporated by reference to Form 8-K filed with the Commission on August 12, 2005.
- 10.4* Employment Agreement by and between Jerry W. Grizzle and Registrant dated effective as of January 25, 2006, incorporated by reference to Form 10-KSB filed with the Commission on April 3, 2006.
- 10.5* Employment Agreement by and between Robin L. Jacob and Registrant dated effective as of February 12, 2006, incorporated by reference to Form 8-K filed with the Commission on April 12, 2006.
- 10.6 Consulting Agreement by and between TVC Consulting and Registrant dated effective as of March 1, 2006, incorporated by reference to Form 10-QSB filed with the Commission on May 15, 2006.
- 10.7 Securities Purchase Agreement dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.8 Secured Convertible Term Note dated June 28, 2006 by the Company in favor of Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.9 Common Stock Purchase Warrant dated June 29, 2006 by the Company in favor of Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.10 Registration Rights Agreement dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.11 Stock Pledge Agreement dated June 28, 2006 by and among the Company, AMS Manufacturing, Inc. and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.12 Master Security Agreement dated June 28, 2006 by and among the Company, AMS Manufacturing, Inc. and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.13 Mortgage dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.14

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

Grant of Security Interest in Patents and Trademarks dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.15 Common Stock Purchase Warrant dated June 28, 2006 by the Company in favor of Ascendant Securities, LLC, incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

36

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

10.16 Engagement Letter between the Company and Ascendant Securities, LLC, incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.17* Employment Agreement by and between Dennis P. Loney and Registrant dated effective as of September 19, 2006, incorporated by reference to Form 8-K filed with the Commission on September 25, 2006.

15 Letter of independent accountants as to unaudited interim financial information, filed herewith.

31.1 Chief Executive Officer Certification, filed herewith.

31.2 Chief Financial Officer Certification, filed herewith.

32.1 Section 1350 Certification of our Chief Executive Officer, filed herewith.

32.2 Section 1350 Certification of our Chief Financial Officer, filed herewith.

* Designates a compensatory plan.